| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/13/2008 | WO2008029601A1 Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient |
| 03/13/2008 | WO2008029565A1 Compound having inhibitory activity on histone deacetylase, and pharmaceutical comprising the compound as active ingredient |
| 03/13/2008 | WO2008029371A1 Pyridin-4-yl derivatives as immunomodulating agents |
| 03/13/2008 | WO2008029370A1 Pyridin-3-yl derivatives as immunomodulating agents |
| 03/13/2008 | WO2008029282A2 Aqueous formulation comprising an antitumor agent |
| 03/13/2008 | WO2008029189A1 Regulation of expression of p140cap protein in tumors |
| 03/13/2008 | WO2008029136A1 Pharmaceutical composition and method for cancer treatment based on combinational use of conventional or plant-derived anticancer agents and geranium oil or compounds thereof |
| 03/13/2008 | WO2008028965A2 Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof |
| 03/13/2008 | WO2008028963A2 Calreticulin for its use as a medication for the treatment of cancer in a mammal |
| 03/13/2008 | WO2008028934A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| 03/13/2008 | WO2008028860A1 Benzotriazole kinase modulators |
| 03/13/2008 | WO2008028617A1 Heteroaryl derivatives as protein kinase inhibitors |
| 03/13/2008 | WO2008028534A1 Aptamers labelled with gallium-68 |
| 03/13/2008 | WO2008028427A1 Derivatives of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization |
| 03/13/2008 | WO2008028336A1 A pharmaceutical composition of scutellarein and scutellarin or baicalin having synergistical antitumor effect |
| 03/13/2008 | WO2008014263A3 Dimeric iap antagonists |
| 03/13/2008 | WO2008013791A3 Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| 03/13/2008 | WO2008007149A3 New medical use of triazine derivatives |
| 03/13/2008 | WO2007143090A3 Hepatocyte growth factor (hgf) binding proteins |
| 03/13/2008 | WO2007138324A3 Materials and complexes for the delivery of biologically-active material to cells |
| 03/13/2008 | WO2007133352A3 Macrocyclic kinase inhibitors |
| 03/13/2008 | WO2007130697A3 Anti-ephb4 antibodies and methods using same |
| 03/13/2008 | WO2007126365A3 Further medical uses of antisecretory protein |
| 03/13/2008 | WO2007125310A3 Pharmaceutical combinations of pk inhibitors and other active agents |
| 03/13/2008 | WO2007123939A8 Novel arylamino n-heteraryls as mek inhibitors |
| 03/13/2008 | WO2007112753A3 Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| 03/13/2008 | WO2007109174A3 Compositions and methods for modulation of mcl-1 expression |
| 03/13/2008 | WO2007099401A3 Oncolytic attenuated reoviruses for treatment of proliferative disorders |
| 03/13/2008 | WO2007095583A3 Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin |
| 03/13/2008 | WO2007089544A3 Biodegradable non-ophthalmic implants and related methods |
| 03/13/2008 | WO2007082914A3 Method of diagnosis and method of treatment |
| 03/13/2008 | WO2007053574A3 Combinations comprising sorafenib and interferon for the treatment of cancer |
| 03/13/2008 | WO2007047998A3 Mutations and polymorphisms of hdac2 |
| 03/13/2008 | WO2007010235A8 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide |
| 03/13/2008 | US20080064887 Paclitaxel or docetaxel synthesis and claimed intermediates; purity; coupling 7,10-diprotected intermediates 7-O-(2-haloacyl)baccatin III or 7,10-O-di-(2-haloacyl)-10-deacetylbaccatin III to 3-[(2-alkyl/aryl-2-trialkylsilyl)ethoxy-carbonyl]-4-aryl-2-substituted-1,3-oxazolidine-5-carboxylic acid |
| 03/13/2008 | US20080064870 Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof |
| 03/13/2008 | US20080064853 Nervous system protein for use in treatment and prevention of nervous system and seizure disorders |
| 03/13/2008 | US20080064764 Isolated nucleic acids; antibody for selective binding; biodrug treating osteoporosis, osteoblast, bone disorders, osteocalcin mediated disorder |
| 03/13/2008 | US20080064762 Composition Comprising a Pharmacologically Active Agent Coupled to a Target Cell Specific Component, and a Saponin |
| 03/13/2008 | US20080064753 Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators |
| 03/13/2008 | US20080064749 Lipoxin Analogs as Novel Inhibitors of Angiogenesis |
| 03/13/2008 | US20080064746 Lipoxins and Aspirin-Triggered Lipoxins and Their Stable Analogs in the Treatment of Asthma and Inflammatory Airway Diseases |
| 03/13/2008 | US20080064733 MAGIs (membrane associated guanylate kinase proteins with inverse orientation); oncosuppressive (tumor suppressor) protein; (2-(1-Hydroxypentyl)-3-(2-phenylethyl)-6-methyl)indole-5-carboxylic acid |
| 03/13/2008 | US20080064729 Phenethylamide derivatives with kinase inhibitory activity |
| 03/13/2008 | US20080064728 Heterocyclic Compounds Useful as Dpp-Iv Inhibitors |
| 03/13/2008 | US20080064722 Agent for promoting interferon-y production |
| 03/13/2008 | US20080064714 Novel Pyrrolodihydroisoquinolines |
| 03/13/2008 | US20080064707 Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 03/13/2008 | US20080064700 Aryl triazines as LPAAT-beta inhibitors and uses thereof |
| 03/13/2008 | US20080064696 Substituted sulphoximines as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 03/13/2008 | US20080064686 Programmed cell death, autoimmunity, inflammation, hyperproliferation; easy formulation, shelf life |
| 03/13/2008 | US20080064683 Oral or intraveinous administration of 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; ELISA analysis; angiogenesis inhibitors; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration |
| 03/13/2008 | US20080064680 Methods for Diagnosis and Treatment of Cancer |
| 03/13/2008 | US20080064676 Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity |
| 03/13/2008 | US20080064673 Cyanopyrrole-phenyl amide progesterone receptor modulators and uses thereof |
| 03/13/2008 | US20080064668 Carbon 20 is substituted with methyl or cyclopropyl, carbon 16 is a single or double bond, and carbon 23 is a single, double, or triple bond; side effect reduction; vitamin deficiency; anticarcinogenic antiarthritic agents; immunotherapy; metabolic disorders; gene expression inhibition of ILT3 |
| 03/13/2008 | US20080064661 Dihydroxyl compounds and compositions for cholesterol management and related uses |
| 03/13/2008 | US20080064651 A 21-base antisense oligonucleotide which inhibits gene expression of testosterone-repressed prostate message-2 by tumor cells; prostate and renal cell cancer; enhanced chemosensitivity, hormone and radiation sensitivities |
| 03/13/2008 | US20080064649 Anticarcinogenic and antiproliferative agents in combination with radiation therapy, chemotherapy, ablative surgery, or partially ablative surgery for bone and breast cancer treatments |
| 03/13/2008 | US20080064647 A polyvalent multimeric complex formed from a plurality of circularly permuted chimeric pRNA molecules, each carrying a stabilized biologically active moiety; degradation resistant stabilized ribozyme is correctly folded such that it remains intracellularly active |
| 03/13/2008 | US20080064634 Disintegrin and microtubule stabilizing agent (small molecule cell division inhibitor); preventing metastasis |
| 03/13/2008 | US20080064096 Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
| 03/13/2008 | US20080064066 Modified human granulocyte-colony stimulating factor and process for producing same |
| 03/13/2008 | US20080063724 Methods and compostions for treating proliferative diseases |
| 03/13/2008 | US20080063715 Extracellular matrix to treat malignancy in mammals |
| 03/13/2008 | US20080063661 treating a wart with a fusion protein comprising (1) a heat shock protein and (2) a human papilloma virus (HPV) protein; Mycobacterium bovis heat shock protein; HPV is an E7 protein; cervical dysplasia, anal cancer, anal dysplasia |
| 03/13/2008 | US20080063653 vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers; nucleic acid; agonist polypeptide derived from a mucin tumor antigen; genetic vaccine |
| 03/13/2008 | US20080063642 Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders |
| 03/13/2008 | US20080063637 Regulation of oncogenesis by Akt-specific isoforms |
| 03/13/2008 | US20080063633 Fusion proteins comprising single chain FV fragment of an antibody, and transport proteins, used for treatment of skin cancer |
| 03/13/2008 | US20080063632 Recombinant host for producing l-asparaginase ii |
| 03/13/2008 | US20080063624 administering compounds which bind to the chemokine receptors, such as 1,1'-[1,4-phenylene-bis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane, optionally with colony stimulating factors, to effect regeneration of dead myocardium |
| 03/13/2008 | US20080063598 chimeric antibodies, fragments, polypeptides and derivatives that preferentially bind tumor associated antigens (AF-20), useful in the treatment and diagnosis of cancers |
| 03/13/2008 | CA2663100A1 Indazole derivatives as modulators of interleukin-1 receptor-associated kinase |
| 03/13/2008 | CA2662998A1 Benzotriazole kinase modulators |
| 03/13/2008 | CA2662693A1 Aptamers labelled with gallium-68 |
| 03/13/2008 | CA2662628A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
| 03/13/2008 | CA2662626A1 Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| 03/13/2008 | CA2662308A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| 03/13/2008 | CA2662031A1 Heteroaryl derivatives as protein kinase inhibitors |
| 03/13/2008 | CA2661878A1 Anti-activin a antibodies and uses thereof |
| 03/13/2008 | CA2661315A1 Pyridin-3-yl derivatives as immunomodulating agents |
| 03/13/2008 | CA2661105A1 Pyridin-4-yl derivatives as immunomodulating agents |
| 03/13/2008 | CA2660685A1 Aqueous formulation comprising an antitumor agent |
| 03/13/2008 | CA2656227A1 Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient |
| 03/12/2008 | EP1897950A2 Human GIL-19/AE289 proteins and polynucleotides encoding same |
| 03/12/2008 | EP1897941A1 Means for increasing intracellular levels of protoporphyrin IX and use thereof |
| 03/12/2008 | EP1897889A2 Method of modulating the profileration of medullary thyroid carcinoma cells |
| 03/12/2008 | EP1897884A1 Physiologically active substance nk13650p3, method of producing the same and use thereof |
| 03/12/2008 | EP1897882A1 N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof |
| 03/12/2008 | EP1897880A1 1,3-benzothiazinone derivative and use thereof |
| 03/12/2008 | EP1897877A2 Process for producing crystal |
| 03/12/2008 | EP1897871A1 Benzenoid ansamycin derivative |
| 03/12/2008 | EP1897870A1 Pharmaceutical composition comprising 2-pyridone derivative as active ingredient |
| 03/12/2008 | EP1897864A1 Anthracene derivatives and the use thereof for treating benign and malignant tumors |
| 03/12/2008 | EP1897562A1 Aptamers labelled with Gallium-68 |
| 03/12/2008 | EP1897561A1 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 03/12/2008 | EP1897553A1 Inhibitor of stem cell proliferation and uses thereof |
| 03/12/2008 | EP1897542A1 Aqueous formulation comprising an antitumor agent |
| 03/12/2008 | EP1897540A2 Inhibition of STAT3 signal transduction for human cancer therapy |